Access to nutrition and behavioral counseling : Referrals to dietitians, diabetes educators, and psychologists improve outcomes
This can lead to rebound weight regain, which can be frustrating
Certain diabetes medications not only control blood sugars but may also help people lose weight
Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, reports injection site reaction rates of approximately 1.7-2.2% in its FDA prescribing information, similar to semaglutide
Patients were included if they had 2 follow-up BMI measurements spanning 2 months during the first 12 months of semaglutide use (1,345 patients contributing 7,751 BMI measurements)
On average, tirzepatide has been shown in research to lead to a greater amount of weight loss : People with obesity in clinical trials for tirzepatide lost, on average, 20% of their body weight at week 72 (and about 7 inches off their waistlines), compared with about 14% of their body weight (and about 5 inches off their waistlines) with semaglutide